Top

Archives of Gynecology and Obstetrics

Published in:

01-09-2017 | Gynecologic Oncology

Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs

Authors: Shujian Xu, Cui Zhao, Zhongming Jia, Xilong Wang, Yong Han, Zhenlin Yang

Published in: Archives of Gynecology and Obstetrics | Issue 3/2017

Abstract

Purpose

Breast cancer is the most common invasive type of cancer among women. Role of different microRNAs (miRNAs) and poly(ADP-ribose) polymerases (PARPs) in breast cancer has been well established. This study aimed to explore the effects of miR-891b on sensitizing breast cancer cells to alkylating chemotherapeutic drugs through PARPs.

Methods

The expression of miR-891b and PARP1 in human breast cancer cells HCC1806 was overexpressed by transfection with their mimics or expressing vector. Then, the transfected cells were exposed to 40 µM N-methyl-N-nitro-N-nitrosoguanidine (MNNG) for 1 h. The correlation between miR-891b and PARP1 was detected by RT-qPCR, western blot, and dual-luciferase reporter assay. Besides, MTT assay and Annexin V assay were done to measure cell proliferation and apoptosis, respectively.

Results

PARP1 was a target of miR-891b, and it was negatively regulated by miR-891b. MiR-891b increased the sensitivity of the HCC1806 cells to the cytotoxic effects of MNNG through suppressing cell proliferation and increasing the percentage of apoptotic cells. Restoration of PARP1 activity in the HCC1806 cells led to loss of miR-891b mediated sensitivity of the HCC1806 cells to MNNG.

Conclusion

MiR-891b increases the sensitivity of the breast cancer cells (HCC1806) to the cytotoxic effects of the chemotherapeutic agent MNNG by suppressing the expression of PARP1.

McGuire A et al (2015) Effects of age on the detection and management of breast cancer. Cancers (Basel) 7(2):908–929CrossRef

McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7(2):418–419CrossRefPubMedPubMedCentral

Cardoso F et al (2017) Research needs in breast cancer. Ann Oncol 28:208–217PubMed

Mustafa M et al (2013) Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 6:CD004253

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1–22CrossRefPubMed

Kim JS et al (2014) MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Mol Cell Biochem 387(1–2):71–79CrossRefPubMed

Diab M et al (2016) The role of microRNAs in the diagnosis and treatment of pancreatic adenocarcinoma. J Clin Med 5(6):59CrossRefPubMedCentral

Zhang B et al (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1):1–12CrossRefPubMed

Meltzer PS (2005) Cancer genomics: small RNAs with big impacts. Nature 435(7043):745–746CrossRefPubMed

10.

Riaz M et al (2013) miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 15(2):R33CrossRefPubMedPubMedCentral

11.

Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:188CrossRefPubMedPubMedCentral

12.

Rouleau M et al (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10(4):293–301CrossRefPubMedPubMedCentral

13.

Shi Wei et al (2016) MiR-449a promotes breast cancer progression by targeting CRIP2. Oncotarget 7(14):18906–18918CrossRefPubMedPubMedCentral

14.

Fang H et al (2017) miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res 9(3):953PubMedPubMedCentral

15.

He J et al (2017) miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2. Oncol Rep 37(5):2672–2678PubMedPubMedCentral

16.

Rodriguez-Barrueco R et al (2017) miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev 31(6):553–566CrossRefPubMed

17.

Zhao G, Li Y, Wang T (2017) Potentiation of docetaxel sensitivity by miR-638 via regulation of STARD10 pathway in human breast cancer cells. Biochem Biophys Res Commun 487:255–261CrossRefPubMed

18.

Fan X et al (2017) MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother 88:507CrossRefPubMed

19.

Hakme A et al (2008) The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: beyond the Usual Suspects’ Review Series. EMBO Rep 9(11):1094–1100CrossRefPubMedPubMedCentral

20.

Schreiber V et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7(7):517–528CrossRefPubMed

21.

Megnin-Chanet F, Bollet MA, Hall J (2010) Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci 67(21):3649–3662CrossRefPubMedPubMedCentral

22.

Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5(4):387–393CrossRefPubMed

23.

Murai J et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599CrossRefPubMedPubMedCentral

24.

Belleannee C et al (2012) Role of microRNAs in controlling gene expression in different segments of the human epididymis. PLoS One 7(4):e34996CrossRefPubMedPubMedCentral

25.

Dong Q et al (2016) MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget 7(50):82338–82353PubMedPubMedCentral

26.

Durkacz BW et al (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283(5747):593–596CrossRefPubMed

27.

Banasik M et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267(3):1569–1575PubMed

28.

AlHilli MM et al (2016) In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol 143(2):379–388CrossRefPubMedPubMedCentral

29.

Rugo HS et al (2016) Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34CrossRefPubMedPubMedCentral

30.

Munroe M, Kolesar J (2016) Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Am J Health Syst Pharm 73(14):1037–1041CrossRefPubMed

Title: Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs
Authors: Shujian Xu
Cui Zhao
Zhongming Jia
Xilong Wang
Yong Han
Zhenlin Yang
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2017
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4444-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2017

Anti-Mullerian hormone (AMH) and embryo quality assessed by time-lapse imaging (TLI): a cross-sectional observational study

Effect of routine rapid insertion of Bakri balloon tamponade on reducing hemorrhage from placenta previa during and after cesarean section

Spontaneous rupture of infarcted leiomyoma into endometrial cavity in a perimenopausal woman

What can we do to reduce the associated costs in induction of labour of intrauterine growth restriction foetuses at term? A cost-analysis study

Fetal cephaloceles: prenatal diagnosis and course of pregnancy in 65 consecutive cases

Maternal serum homocysteine and uterine artery Doppler as predictors of preeclampsia and poor placentation